CD274 and non-small cell lung carcinoma: The open-label, randomized, phase III clinical study CheckMate 026 compared first-line nivolumab with chemotherapy in 423 previously untreated patients with PD-L1-positive (PD-L1 ≥ 5%) NSCLC.